Chen Zhang

Chen Zhang is an experienced leader in analytical development and CMC with a robust background in managing complex programs across various biopharmaceutical companies. Currently serving as Director, Analytical Development at Innoviva Specialty Therapeutics, Inc., Chen Zhang previously held the position of Head/Director, Analytical Development CMC at Proteovant Therapeutics, effectively leading multiple global CDMOs. Prior roles include Director of Analytical CMC at TG Therapeutics, Sr. Manager of Analytical CMC Strategy at Bristol Myers Squibb, and extensive contributions as Scientist at Celgene, Merck, and Novo Nordisk. Academic qualifications include a B.S. in Chemistry from Peking University and a Ph.D. in Chemistry from the University of Illinois Urbana-Champaign.